Novel strategies for enhanced analysis of repeat disorders

Information

  • Research Project
  • 9622029
  • ApplicationId
    9622029
  • Core Project Number
    R43HD095788
  • Full Project Number
    1R43HD095788-01A1
  • Serial Number
    095788
  • FOA Number
    PA-17-302
  • Sub Project Id
  • Project Start Date
    9/1/2018 - 5 years ago
  • Project End Date
    8/31/2019 - 4 years ago
  • Program Officer Name
    KING, TRACY
  • Budget Start Date
    9/1/2018 - 5 years ago
  • Budget End Date
    8/31/2019 - 4 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/31/2018 - 5 years ago
Organizations

Novel strategies for enhanced analysis of repeat disorders

Summary The goal of this project is to establish feasibility for diagnostic sequencing of clinically relevant short tandem repeat (STR) DNA markers on the 3rd generation MinION nanopore (NP) sequencing platform, using tailored STR-specific reagents and analytical software. This new and innovative modality has the potential to create a paradigm shift in clinical-research and diagnostics of repeat disorder, as it can ultimately bring the analysis of recalcitrant STR DNA elements up to par with current genetic NGS assay standards. Our approach leverages the platform?s unique long- and direct-read capabilities for STR applications and comprehensively addresses current NP platform limitations and STR-specific challenges through innovative wetware and interpretive software. Successful implementation of Oxford Nanopore?s sequencing technology for STR analysis will allow high resolution and comprehensive long-range genotyping, improve sample- and gene-multiplexing capabilities, streamline genetic testing workflows and reduce turn-around-time, while markedly shrinking laboratory capital costs and instrumentation footprint to a < $1000 pocket-sized device. Proof of principle for STR sequencing will be pursued for the Fragile-X associated CGG repeat region in the FMR1 gene in the context of a much needed high-throughput and comprehensive Fragile X carrier screening application that will provide FMR1 allele specific sizing and AGG analysis across 96 samples in a single reaction and less than 10 hours to results. Fragile X carrier screening is supported by professional testing guidelines and routinely performed, therefore a single assay that can provide streamlined allele-specific CGG repeat length and AGG interruption profiles is positioned to benefit hundreds of thousands of individuals per year.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
  • Activity
    R43
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
    NICHD:224999\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ASURAGEN, INC.
  • Organization Department
  • Organization DUNS
    622988330
  • Organization City
    AUSTIN
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    787441038
  • Organization District
    UNITED STATES